Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of semaglutide once-weekly versus insulin aspart three times daily, both as add on to metformin and optimised insulin glargine (U100) in subjects with type 2 diabetes A 52-week, multi-centre, multinational, open-label, active-controlled, two armed, parallel-group, randomised trial in subjects with type 2 diabetes

Next Previous
Search
Trial Profile

Effect of semaglutide once-weekly versus insulin aspart three times daily, both as add on to metformin and optimised insulin glargine (U100) in subjects with type 2 diabetes A 52-week, multi-centre, multinational, open-label, active-controlled, two armed, parallel-group, randomised trial in subjects with type 2 diabetes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary) ; Insulin aspart; Insulin glargine; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms SUSTAIN 11
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 16 Jan 2023 Results of cost-effectiveness analysis of Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK published in the Diabetes, Obesity and Metabolism
    • 02 Mar 2021 Status changed from active, no longer recruiting to completed.
    • 19 Nov 2020 Planned primary completion date changed from 29 Oct 2020 to 21 Jan 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top